98%
921
2 minutes
20
Breast cancer is one of the most common tumors in women, and early screening can significantly reduce mortality rates. Meanwhile, accurately identifying HER2-positive and HER2-negative subtypes of breast cancer is critical for helping doctors determine treatment options and prognosis strategies for patients. The goal of this study was to develop a computationally efficient, end-to-end model capable of both breast cancer detection and molecular typing prediction without the need for complex feature engineering. This study collected serum samples from 541 volunteers, including HER2-positive, HER2-negative, ductal carcinoma in situ (DCIS) patients, and healthy individuals. After sample collection, Raman spectra were obtained using a Raman spectrometer with a 532 nm excitation wavelength. Based on an efficient channel attention mechanism and convolutional neural networks, a classification model was developed to facilitate breast cancer detection and molecular subtyping. The proposed model significantly reduced the number of parameters and increased training speed. On an unknown test set, the model achieved an accuracy of 94.5 % and an AUC of 0.952, outperforming traditional models and algorithms. Specifically, the model achieved an accuracy of 98.1 % for BC, DCIS, and healthy volunteers, and 89.5 % for HER2-positive and HER2-negative cases. Additionally, the model's effectiveness was validated using different datasets, yielding satisfactory results. Raman spectroscopy, combined with our proposed attention mechanism-based convolutional neural network, effectively enables early screening and molecular subtype prediction of breast cancer. These findings offer new possibilities for rapid, non-invasive, and low-cost early screening and molecular subtype prediction of breast cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.saa.2025.126396 | DOI Listing |
Mol Cancer Ther
September 2025
Case Western Reserve University School of Medicine, Cleveland, OH, United States.
The estrogen receptor (ER or ERα) remains the primary therapeutic target for luminal breast cancer, with current treatments centered on competitive antagonists, receptor down-regulators, and aromatase inhibitors. Despite these options, resistance frequently emerges, highlighting the need for alternative targeting strategies. We discovered a novel mechanism of ER inhibition that targets the previously unexplored interface between the DNA-binding domain (DBD) and ligand-binding domain (LBD) of the receptor.
View Article and Find Full Text PDFJ Med Chem
September 2025
Department of Natural Products and Medicinal Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India.
Nitric oxide (NO) is a multifunctional signaling molecule in oncology, influencing tumor progression, apoptosis, and immune responses. In contrast, chlorambucil (Cbl), a DNA-alkylating chemotherapeutic, induces cytotoxicity through DNA damage. Here, we report a photoresponsive nanoparticle platform for sequential codelivery of NO and Cbl, where NO is released within 10 min of irradiation, followed by Cbl release within 30 min.
View Article and Find Full Text PDFJ Am Acad Audiol
September 2025
Paraneoplastic cerebellar degeneration (PCD) is a rare neurological disorder caused by tumor-mediated antibodies targeting the cerebellum, often leading to irreversible cerebellar damage. The most common antibody implicated in PCD is anti-Purkinje cell cytoplasmic antibody type-1, associated with malignancies such as breast, gynecological, and lung cancers. Symptoms often include dizziness, imbalance, progressive ataxia, and other cerebellar signs/symptoms, but early presentations may mimic acute vestibular syndrome, thus complicating diagnosis.
View Article and Find Full Text PDFStem Cell Rev Rep
September 2025
Paris Cité University, INSERM UMR-S 970, Paris Cardiovascular Research Centre, Paris, France.
Endothelial Colony-Forming Cells (ECFCs) are recognized as key vasculogenic progenitors in humans and serve as valuable liquid biopsies for diagnosing and studying vascular disorders. In a groundbreaking study, Anceschi et al. present a novel, integrative strategy that combines ECFCs loaded with gold nanorods (AuNRs) to enhance tumor radiosensitization through localized hyperthermia.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.